Skip to main content
SpringerLink
Log in

Spécificités de la prise en charge du CBNPC chez les sujets âgés

Treatment of NSCLC in elderly patients in detail

  • Mise Au Point / Update
  • Published:
Oncologie

Résumé

Le cancer bronchique non à petites cellules (CBNPC) est une maladie majoritairement du sujet âgé, son incidence devrait augmenter dans les pays occidentaux en raison du vieillissement de la population. Malgré tout, les données disponibles sur la prise en charge de ces patients restent relativement limitées comparativement à celles concernant les sujets plus jeunes. Des recommandations internationales ont été émises, mais leur application est rendue difficile par l’absence de définition consensuelle des fragilités à prendre en considération dans la décision de traitement et des adaptations de traitement que celles-ci nécessitent. L’objet de cet article est de synthétiser les données de la littérature disponibles pour la prise en charge des sujets âgés atteints d’un CBNPC aux différents stades: précoces, localement avancés et métastatiques. Nous aborderons par ailleurs la place de l’oncogériatrie dans la prise en charge de ces patients.

Abstract

Non-small cell lung cancer (NSCLC) is a very common disease of the elderly, and its incidence is expected to increase in Western countries because of the ageing of the population. Despite this, data available to challenge elderly patients with NSCLC are limited compared to younger patients. International recommendations have been published but they are difficult to apply because of the lack of consensual definition of frailties relevant to make decision of treatment and to adapt it. The purpose of this article is to synthesize the published data available to challenge elderly patients with NSCLC at various stages: early, locally advanced and inoperable, and metastatic. We also discuss data about the use of comprehensive geriatric assessment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. http://seer.cancer.gov/statfacts/html/lungb.html

  2. Debieuvre D, Locher C, Neidhardt AC, et al (2014) Ten-year evolution in non-small cell lung cancer according to sex. Results of the KBP-2010-CPHG study by the College of General Hospital Respiratory Physicians. Rev Mal Respir 31:805–16

    Article  CAS  PubMed  Google Scholar 

  3. Giroux-Leprieur E, Labrune S, Giraud V, et al (2012) Delay between the initial symptoms, the diagnosis and the onset of specific treatment in elderly patients with lung cancer. Clin Lung Cancer 13:363–8

    Article  PubMed  Google Scholar 

  4. HowladerN, NooneAM, KrapchoM, et al (1975–2010) SEER Cancer Statistics Review, National Cancer Institute. Bethesda (MD); http://seer.cancer.gov/csr/1975_2010/

  5. Davidoff AJ, Gardner JF, Seal B, et al (2011) Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol 6:934–41

    Article  PubMed  Google Scholar 

  6. Extermann M, Albrand G, Chen H, et al (2003) Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol 21:3214–9

    Article  PubMed  Google Scholar 

  7. Dell’Amore A, Monteverde M, Martucci N, et al (2015) Lobar and sub-lobar lung resection in octogenarians with early stage non-small cell lung cancer: factors affecting surgical outcomes and long-term results. Gen Thorac Cardiovasc Surg 63:222–30

    Article  PubMed  Google Scholar 

  8. Brokx HA, Visser O, Postmus PE, et al (2007) Surgical treatment for octogenarians with lung cancer: results from a populationbased series of 124 patients. J Thorac Oncol 2:1013–7

    Article  PubMed  Google Scholar 

  9. Kalathiya RJ, Saha SP (2012) Pneumonectomy for non-small cell lung cancer: outcomes analysis. South Med J 105:350–4

    Article  PubMed  Google Scholar 

  10. Zuin A, Marulli G, Breda C, et al (2010) Pneumonectomy for lung cancer over the age of 75 years: is it worthwhile? Interact Cardiovasc Thorac Surg 10:931–5

    Article  PubMed  Google Scholar 

  11. Gray SW, Landrum MB, Lamont EB, et al (2012) Improved outcomes associated with higher surgery rates for older patients with early stage non-small cell lung cancer. Cancer 118:1404–11

    Article  PubMed  Google Scholar 

  12. Shapiro M, Mhango G, Kates M, et al (2012) Extent of lymph node resection does not increase perioperative morbidity and mortality after surgery for stage I lung cancer in the elderly. Eur J Surg Oncol 38:516–22

    Article  CAS  PubMed  Google Scholar 

  13. Okasaka T, Usami N, Taniguchi T, et al (2010) Can nonperformance of radical systematic mediastinal lymphadenectomy be justified in elderly lung cancer patients? An evaluation using propensity-based survival analysis. Eur J Cardiothorac Surg 38:27–33

    Article  PubMed  Google Scholar 

  14. Port JL, Mirza FM, Lee PC, et al (2011) Lobectomy in octogenarians with non-small cell lung cancer: ramifications of increasing life expectancy and the benefits of minimally invasive surgery. Ann Thorac Surg 92:1951–7

    Article  PubMed  Google Scholar 

  15. Kiernan PD, Khandhar SJ, Fortes DL, et al (2011) Thoracic surgery in octogenarians: CVTSA/Inova Fairfax hospital experience, 1990 to 2009. Am Surg 77:675–80

    PubMed  Google Scholar 

  16. Nakanishi R, Yamashita T, Oka S (2010) Video-assisted thoracic surgery lobectomy for non-small cell lung cancer in patients with a Charlson comorbidity index score of two or more. J Thorac Oncol 5:56–61

    Article  PubMed  Google Scholar 

  17. Cattaneo SM, Park BJ, Wilton AS, et al (2008) Use of videoassisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg 85:231–5

    Article  PubMed  Google Scholar 

  18. Bolukbas S, Eberlein MH, Schirren J (2011) Pneumonectomy vs. sleeve resection for non-small cell lung carcinoma in the elderly: analysis of short-term and long term results. Thorac Cardiovasc Surg 59:142–7

    Article  CAS  PubMed  Google Scholar 

  19. Okami J, Ito Y, Higashiyama M, et al (2010) Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. Ann Thorac Surg 90:1651–6

    Article  PubMed  Google Scholar 

  20. Cheng YD, Duan CJ, Dong S, et al (2012) Clinical controlled comparison between lobectomy and segmental resection for patients over 70 years of age with clinical stage I non-small cell lung cancer. Eur J Surg Oncol 38:1149–55

    Article  CAS  PubMed  Google Scholar 

  21. Rivera C, Falcoz PE, Bernard A, et al (2011) Surgical management and outcomes of elderly patients with early stage non-small cell lung cancer: a nested case-control study. Chest 140:874–80

    Article  PubMed  Google Scholar 

  22. Pignon JP, Tribodet H, Scagliotti GV, et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552–9

    Article  PubMed  Google Scholar 

  23. Pepe C, Hasan B, Winton TL, et al (2007) Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 25:1553–61

    Article  CAS  PubMed  Google Scholar 

  24. Früh M, Rolland E, Pignon JP, et al (2008) Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer. J Clin Oncol 26:3573–81

    Article  PubMed  Google Scholar 

  25. Wisnivesky JP, Smith CB, Packer S, et al (2011) Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II–IIIA lung cancer: observational cohort study. BMJ 343:d4013

    Article  PubMed  PubMed Central  Google Scholar 

  26. Coate LE, Massey C, Hope A, et al (2011) Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol 6:537–44

    Article  PubMed  Google Scholar 

  27. Wanders R, Steevens J, Botterweck A, et al (2011) Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: a prospective population-based study. Eur J Cancer 47:2691–7

    Article  PubMed  Google Scholar 

  28. Davidoff AJ, Gardner JF, Seal B, et al (2011) Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J Thorac Oncol 6:934–41

    Article  PubMed  Google Scholar 

  29. Atagi S, Kawahara M, Yokoyama A, et al (2012) Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small cell lung cancer: a randomised, controlled, phase III trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 13:671–8

    Article  CAS  PubMed  Google Scholar 

  30. Mok TS, Wu YL, Thongprasert S, et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–57

    Article  CAS  PubMed  Google Scholar 

  31. Han JY, Park K, Kim SW, et al (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in neversmokers with adenocarcinoma of the lung. J Clin Oncol 30:1122–8

    Article  CAS  PubMed  Google Scholar 

  32. Maemondo M, Inoue A, Kobayashi K, et al (2010) North-East Japan Study Group. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 362:2380–8

    Article  CAS  PubMed  Google Scholar 

  33. Zhou C, Wu YL, Chen G, et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase III study. Lancet Oncol 12:735–42

    Article  CAS  PubMed  Google Scholar 

  34. Rosell R, Carcereny E, Gervais R, et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase III trial. Lancet Oncol 13:239–46

    Article  CAS  PubMed  Google Scholar 

  35. Sequist L, Chih-Hsin Yang J, Yamamoto N, et al (2013) zhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31:3327–34

    Article  CAS  PubMed  Google Scholar 

  36. Wu YL, Zhou C, Hu CP, et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase III trial. Lancet Oncol 15:213–22

    Article  CAS  PubMed  Google Scholar 

  37. Wheatley-Price P, Ding K, Seymour L, et al (2008) Erlotinib for advanced non-small cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26:2350–7

    Article  CAS  PubMed  Google Scholar 

  38. Maemondo M, Minegishi Y, Inoue A, et al (2012) First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol 7:1417–22

    Article  CAS  PubMed  Google Scholar 

  39. Inoue A, Kobayashi K, Usui K, et al (2009) First-line gefitinib for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–400

    Article  CAS  PubMed  Google Scholar 

  40. Asami K, Koizumi T, Hirai K, et al (2011) Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer 12:387–92

    Article  CAS  PubMed  Google Scholar 

  41. Shaw AT, Kim DW, Nakagawa K, et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–94

    Article  CAS  PubMed  Google Scholar 

  42. Solomon BJ, Mok T, Kim DW, et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–77

    Article  PubMed  Google Scholar 

  43. Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91:66–72

    Article  Google Scholar 

  44. Kudoh S, Takeda K, Nakagawa K, et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24:3657–63

    Article  CAS  PubMed  Google Scholar 

  45. Gridelli C, Maione P, Rossi A (2007) Single-agent chemotherapy for the treatment of elderly patients with advanced non-small cell lung cancer: what is the best drug? J Clin Oncol 25:1444–5

    Article  CAS  PubMed  Google Scholar 

  46. Gridelli C, Perrone F, Gallo C, et al (2003) Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–72

    Article  CAS  PubMed  Google Scholar 

  47. Quoix E, Zalcman G, Oster JP, et al (2011) Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-0501 randomised, phase III trial. Lancet 378:1079–88

    Article  CAS  PubMed  Google Scholar 

  48. Abe T, Takeda K, Ohe Y, et al (2015) Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. J Clin Oncol 33:575–81

    Article  CAS  PubMed  Google Scholar 

  49. Ramalingam SS, Dahlberg SE, Langer CJ, et al (2008) Outcomes for elderly, advanced-stage non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 26:60–5

    Article  CAS  PubMed  Google Scholar 

  50. Leighl NB, Zatloukal P, Mezger J, et al (2010) Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 5:1970–6

    Article  PubMed  Google Scholar 

  51. Crinò L, Dansin E, Garrido P, et al (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small cell lung cancer (SAiL, MO19390): a phase IV study. Lancet Oncol 11:733–40

    Article  PubMed  Google Scholar 

  52. Repetto L, Fratino L, Audisio RA, et al (2002) Comprehensive geriatric assessment adds information to Eastern Cooperative Oncolgy Group performance status in elderly cancer patients: An italian Group for Geriatric Oncology Study. J Clin Oncol 20:494–502

    Article  PubMed  Google Scholar 

  53. Balducci L, Extermann M (2000) Management of cancer in the older person: a practical approach. The Oncologist 5:224–37

    Article  CAS  PubMed  Google Scholar 

  54. Puts MT, Santos B, Hardt J, et al (2014) An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol 25:307–15

    Article  CAS  PubMed  Google Scholar 

  55. Corre R, Greillier L, Le Caër H, et al (2016) Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small cell lung cancer: The phase III randomized ESOGIA-GFPC-GECP 08-02 Study. J Clin Oncol 34: 1476–83

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de pneumologie, CHU Pontchaillou, 2, rue Henri-le-Guilloux, F-35000, Rennes, France

    R. Corre

  2. Service de pneumologie, centre hospitalier de la Dracénie, route de Montferrat, F-83300, Draguignan, France

    H. Le Caer

Authors
  1. R. Corre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Le Caer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Corre.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Corre, R., Le Caer, H. Spécificités de la prise en charge du CBNPC chez les sujets âgés. Oncologie 18, 401–408 (2016). https://doi.org/10.1007/s10269-016-2637-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-016-2637-1

Mots clés

Keywords

Search

Navigation